ロード中...
Bortezomib Reduces Preexisting Antibodies to Recombinant Immunotoxins in Mice()
Recombinant immunotoxin (RIT) therapy is limited in patients by neutralizing antibody responses. Ninety percent of patients with normal immune systems make neutralizing antibodies after one cycle of RIT, preventing repeated dosing. Furthermore, some patients have preexisting antibodies from environm...
保存先:
| 出版年: | J Immunol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4323725/ https://ncbi.nlm.nih.gov/pubmed/25560410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1402324 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|